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ABSTRACT  
Study Objectives: Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease 
due to loss of motor neurons. However, the Autonomic Nervous System (ANS) can also be 
involved. The aim of this research was to assess the sleep macro- and micro-structure, the cardiac 
ANS during sleep and the relationships between sleep, autonomic features and clinical parameters 
in a cohort of ALS patients. 
Methods: Forthy-two consecutive ALS patients underwent clinical evaluation and full-night video-
polysomnography (video-PSG). Only 31 patients met inclusion criteria (absence of comorbidities, 
intake of cardioactive drugs, or recording artifacts) and were selected for assessment of sleep 
parameters, including cyclic alternating pattern (CAP) and heart rate variability (HRV). Subjective 
sleep quality and daytime vigilance were also assessed using specific questionnaires. 
Results: Although sleep was subjectively perceived as satisfactory, compared to age- and sex-
matched healthy controls, ALS patients showed significant sleep alteration: decreased total sleep 
time and sleep efficiency, increased nocturnal awakenings, inverted stage 1 (N1) / stage 3 (N3) 
ratio, reduced REM sleep and decreased CAP rate, the latter supported by lower amounts of A 
phases with an inverted A1/A3 ratio. Moreover, a significant reduction in HRV parameters was 
observed during all sleep stages, indicative of impaired autonomic oscillations.  
Conclusion: Our results indicate that sleep is significantly disrupted in ALS patients despite its 
subjective perception. Moreover, EEG activity and autonomic functions are less reactive, as shown 
by a decreased CAP rate and a reduction in HRV features, reflecting an unbalanced autonomic 
modulation. 
 
Keywords: Amyotrophic lateral sclerosis (ALS); heart rate variability (HRV); sleep and 
neurodegenerative disorders; autonomic nervous system (ANS) 
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Statement of significance: amyotrophic lateral sclerosis is a neurodegenerative disease 
characterized by prominent motor involvement, with alteration also in other systems like autonomic 
nervous system and sleep. In our polysomnographic study of a cohort of ALS patients we 
confirmed that sleep structure in these patients is altered and for the first time we found an 
alteration of CAP with decreased CAP rate due to reduced amount of A1 phases; moreover, we 
demonstrated a subclinical autonomic dysfunction present since the early stages of the disease, as 
shown by reduced heart rate variability (HRV) in all sleep stages. HRV assessment during sleep is a 
not-invasive early tool to investigate autonomic function and decreased HRV is associated with 
increased risk in mortality for cardiac sudden arrest, and low HRV is a strong predictor of increased 
mortality for coronary events, which occurs more frequently at night.  
It is fundamental performing a PSG study since the earliest stages of the disease. 
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Introduction 
Amyotrophic lateral sclerosis (ALS), is an adult-onset inexorably progressive, devastating and fatal 
neurodegenerative disease, characterized by progressive loss of spinal, bulbar and cortical motor 
neurons with consequent painless paralysis of striatal skeletal and bulbar muscles, with dysphagia, 
dysarthria and respiratory impairment, up to respiratory failure. So far, no reversible treatment for 
ALS is available, and death occurs typically within 2-3 years after disease onset.
1
 Although ALS 
has traditionally been considered a pure motor neuron disease, with the concomitant presence of 
symptoms and signs involving other systems suggesting alternative diagnoses, the evidence of 
involvement of other domains (e.g. sensitive, cognitive, autonomic nervous system) has been 
documented, configuring ALS as a multisystem disorder.
2–4
 
Autonomic dysfunctions with impairment of cardiovascular control in ALS have been observed 
especially in the advanced stages of the disease and during sleep.
3,5,6
 In addition, degeneration of 
intermediolateral column neurons
6
 and involvement of the hypothalamus
7
 have been described. 
Dysautonomia, in particular reduced heart rate variability (HRV) and increased sympathetic tone 
have been identified as mortality risk factors in patients with cardiac disease.
5,8
 Sudden death and 
cardiovascular dysfunction due to dysautonomia are probably more frequent during sleep in patients 
affected by ALS.
9,10
 
Sleep fragmentation and sleep disorders may be early manifestations in ALS patients, although 
underdiagnosed. Several factors may disturb sleep in these patients, namely sleep disordered 
breathing, nycturia, sleep fragmentation, restless legs syndrome, nocturnal cramps, pain, depression, 
difficulty in changing position, problems in swallowing, and troublesome cough.
11–13
 Most sleep 
studies in ALS have predominantly focused on the chronic nocturnal respiratory insufficiency and 
hypoventilation
14
 that commonly anticipate the onset of awake respiratory failure, because of the 
physiologic vulnerability of respiration during sleep.  
Sleep is an ideal condition to study the Autonomic Nervous System (ANS), as the automatic control 
of vegetative functions occurs without complete consciousness and reduced external influences. 
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 5 
Nevertheless, few overnight polysomnographic studies have been performed in patients affected by 
ALS
13,15
, and a complete evaluation of the ANS during sleep and of sleep EEG microstructure 
through the study of the Cyclic Alternating Pattern (CAP)
16,17
 is still lacking. 
The present study aims to better characterize the clinical features of ALS beyond the motor 
features, through extensive evaluation of nocturnal sleep, including sleep quality, EEG oscillations 
and autonomic function during both sleep and quiet wakefulness.  
 
Methods 
Among the patients affected by ALS referred to the motor neuron disease outpatients service at the 
University of Cagliari, thirty-one were consecutively enrolled in the study at the Sleep Center, 
University of Cagliari. Diagnosis of ALS was made according to El-Escorial revised criteria.
18
 
Exclusion criteria are reported in Table 1. Twenty-six sex- and age-matched healthy controls were 
selected according to the criteria detailed in Table 1. 
Each subject underwent a clinical and instrumental examination. 
The study was approved by local ethical committee (protocol no. 2013/3205). 
 
Clinical evaluation.  
Each patient underwent thorough history, neurological and general examination, and questionnaires 
for screening sleep disorders:
19
 Epworth Sleepiness Scale (ESS),
20
 Pittsburgh Sleep Questionnaire 
Index (PSQI),
21
 Berlin Questionnaire (BQ),
22
 Restless Legs Syndrome Diagnostic Interview 
(RLSDI), and if positive Restless Legs Syndrome Severity Rating Scale (IRLSRS),
23
 REM 
behavior Disorder Screening Questionnaire  (RBDSQ)
24
. ALS severity was measured by the 
Revised ALS Functional Rating Scale  (ALSFRS-revised),
25
 and by the ALS Severity Scale 
(ALSSS)
26
). The meaning of these questionnaires and evaluating scales is detailed in Table 2. 
 
Instrumental evaluation. 
D
ow
nloaded from
 https://academ
ic.oup.com
/sleep/advance-article-abstract/doi/10.1093/sleep/zsz164/5532811 by U
niversità di C
agliari user on 19 July 2019
Ac
ce
pte
d M
an
us
cri
pt
 
 6 
Each subject underwent a full-night video-polysomnography (video-PSG) recording (Morpheus – 
Micromed®), carried out in a standard sound-attenuated sleep laboratory, attended by an expert 
technician. The following data were included in the PSG study: EEG (3 channels: one frontal, one 
central, and one occipital, referred to the contralateral earlobe); electrooculogram (electrodes placed 
1 cm above the right cantus and 1 cm below the left cantus); electromyogram (EMG) of submental 
muscle, EMG of bilateral tibialis anterior muscle; one single-lead ECG. During the same night, 
sleep respiratory pattern was assessed by means of nasal airflow (nasal pressure cannula), thoracic 
and abdominal respiratory effort, and oxygen saturation (pulse-oximetry). 
Sleep stages, respiratory and legs activity were scored manually by a clinical neurophysiologist 
expert in sleep medicine (PC), following standard criteria.
27
  
The CAP scoring was automatically performed with the Embla® RemLogic™ PSG Software 
(Embla Systems) and then visually checked and manually corrected on the basis of standard criteria 
17
 by a neurologist expert in sleep medicine (GM). The following CAP variables were measured: 
CAP time (time of CAP in NREM sleep), CAP rate (the percentage ratio of CAP time to total 
NREM sleep time) in total NREM sleep, number of A phases, and the prevalence of each phase A 
subtype (A1, A2, A3). For more details on the scoring rules of CAP see Fig S1. 
Quantitative analysis of HRV was performed in Matlab (The Mathworks, Natick, MA) using the 
ECG signal by a biomedical engineer (SM).  
Two separate HRV analyses were performed for each subject: a global analysis of the whole night, 
starting from sleep onset and ending at sleep offset and an analysis of 5-minute segments of the RR. 
The 5-minutes segments were flagged as belonging to wake, NREM, light NREM sleep (N1 and 
N2), deep NREM sleep (N3) and total NREM sleep if at least 80% of the segment was scored as the 
corresponding sleep stage. Mixed segments were discarded. Then, for each subject, we calculated 
the median value of each feature over the epochs corresponding to a certain sleep stage. We decided 
to perform both a stage-to-stage analysis and a full-night analysis for several reasons. In fact, full-
night analysis allows to look at sleep as a “continuum” state independent from the empiric division 
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 7 
into well-defined and stiff stages of 30 seconds, thus offering a more comprehensive look at longer-
term dynamics (e.g. VLF power), which can otherwise be limited by the duration of each single 
sleep stage. On the other hand, the stage-to-stage analysis allows to point up all the continuous 
autonomic changes in correlation to the specific sleep stages. 
The included HRV features were recommended by the Task Force of the European Society of 
Cardiology and the North American Society for Pacing and Electrophysiology:
28
 7 time-domain 
features: mean NN interval (NN), standard deviation of the NN intervals (SDNN), standard 
deviation of the average NN intervals (SDANN), mean of the 5-minute standard deviations of NN 
intervals calculated over the entire recording (SDNN index), square root of the mean squared 
differences of successive NN intervals (RMSSD), proportion of interval differences of successive 
NN intervals greater than 50 ms (pNN50) and proportion of interval differences of successive NN 
intervals greater than 20 ms (pNN20); and 5 frequency-domain features: Very low frequency 
(VLF), low frequency (LF), high frequency (HF), the total spectral power (total power), and the 
LF/HF ratio (LF/HF).
29–32
  Further information about HRV analysis is reported in Method S1.  
We elected to calculate both time- and frequency-domain HRV features since each class 
complements the other in terms of the information it provides on the cardiac autonomic control. In 
fact, while there are significant known correlations between time- and frequency-domain features, 
e.g. between pNN50 and HF power, or between SDANN and total power, the full ensemble 
provides the optimal description of the activity of the ANS. 
 
Statistical analysis 
The statistical analyses were performed using Stata software (version 13, StataCorp, College 
Station, US), Prism 7 for Mac OS X - GraphPad software and Matlab (Mathworks, Natick, MA) 
with a type I error set at 0.05. Continuous parameters were expressed mean ± standard-deviation or 
median [interquartile range], according to statistical distribution. The assumption of normality was 
evaluated using D'Agostino-Pearson Normality test. Description of specific tests used is reported in 
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 8 
the results section and in the tables’ legends. More precisely, the comparisons between patients and 
controls were conducted using Student t-test or Mann-Whitney test if the assumptions of t-test were 
not met, HRV features extracted for the whole night and for the different sleep states were 
compared between ALS patients and healthy controls by means of a non-parametric Kruskal-Wallis 
t-test. The homoscedasticity was analyzed using the Fisher-Snedecor test. As proposed by some 
statisticians (Feise, 2002; Rothman, 1990)
33,34
 a particular focus was also given to the magnitude of 
differences, in addition to inferential statistical tests expressed using p-values. Then, the assessment 
of relationships between quantitative parameters (for example between HRV features in time- and 
frequency- domain of whole night recording and ALSFRS score, or between clinical parameters 
and sleep scoring parameters) was measured using Spearman’s correlation coefficient, applying a 
Sidak’s type I error correction for multiple comparisons. For correlated data (several measures for a 
same subject), random-effects models were carried out to take into account between and within 
patient variability. The normality of residuals was checked for each random-effects model. When 
appropriate, a logarithmic transformation was proposed to achieve the normality of dependent 
variables. 
 
Results 
Thirty-one patients (mean age 63.94 y  10.17; 12 F, 19 M; with mean age at disease onset of 60.74 
y  10.93) satisfied eligibility criteria and were enrolled in the study. 
They were compared to 26 control subjects similar for age and sex (mean age 62.19 y  13.93; 13 
M). Among the 26 control subjects, only 23 underwent to complete CAP and HRV assessment due 
to recordings artifact in the other 3. 
Demographic and clinical data are reported in Table 3. 
 
Clinical evaluation 
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 9 
ALS patients presented a mean  std ALS-FSR score of 32.38  8.86, and a mean  std ALSSS 
score of 29.17  5.42. At disease onset 4 patients had a predominantly bulbar localization, 4 
patients had a generalized localization, and the other ones had a predominantly spinal localization. 
Patients and controls had similar ESS score (5.39  3.45 vs 5.04  2.25; p=0.6604), and PSQI (8.9  
4.4 vs 8.46  2.30; p=0.6492), nineteen patients had high risk of OSAS according to BQ, while no 
patients received a clinical diagnosis of RLS or RBD.   
 
Sleep architecture   
Sleep parameters found in the two groups are reported in Table 4.  
Compared to control subjects, ALS patients presented an impaired sleep structure characterized by 
decreased SE – sleep efficiency (p<0.0001), due to a shorter TST – total sleep time (p=0.0025) and 
to an increased amount of WASO – wake after sleep onset (p<0.0001). The distribution of sleep 
stages was also altered with respect to the control subjects, with increased percentage of sleep stage 
N1 (p<0.0001) and a decreased percentage of REM sleep (p<0.0001). Finally, the N1/N3 ratio (the 
ratio between the percentage of N1 and N3 sleep stages) was inverted and about four times higher 
in patients, mostly due to an increased amount of sleep stage N1 in patients (p<0.0001).  
The hypnogram of a representative patient is illustrated in Fig 1a, showing an irregular sleep 
macrostructure characterized by repetitive stage shifts, numerous awakenings of different duration, 
increased N1 sleep stage and decreased REM sleep.  
Respiratory and movement scoring parameters are reported in Table S1. 
Heart rate and breathing rate of patients and control subjects are reported in Table 4-bis.  
 
Sleep microstructure (CAP)  
CAP parameters are reported in Table 5. 
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 10 
Compared to control subjects, patients affected by ALS had a significant reduction of CAP time 
(p=0.0096) and CAP rate (p=0.011), a decreased number of total A phases (p=0.0015), a decreased 
percentage of A1 phases (p<0.0001), an increased percentage of A3 phases (p<0.0001), and an 
inverted A1/A3 ratio (the ratio between the percentage of A1 and A3) (p<0.0001), which was three 
times lower in ALS patients than in controls. (see Fig 1b). 
 
Quantitative Analysis of Heart Rate Variability 
Table 6 reports the p-values from the Kruskal-Wallis test for features calculated for the whole night 
and using the median of 5-min windows for wakefulness, NREM, REM, light sleep and deep sleep.  
Concerning the full night analysis, pNN20, LF and LF/HF were significantly lower in ALS patients 
compared to controls. 
State-specific analysis showed that during wakefulness, SDNN, SDNN index, RMSSD, pNN50, 
pNN20, total power, VLF, LF and HF were all lower in ALS patients. During NREM sleep, SDNN, 
pNN20, total power, VLF, LF and HF were lower in ALS patients compared to controls. Similar 
results, with the exception of SDNN, were found for light sleep, while in deep sleep, only HF was 
significantly lower in the ALS cohort compared to controls. During REM sleep, SDNN, RMSSD, 
pNN50, pNN20, total power, LF, HF, and LF/HF were significantly lower in ALS compared to 
controls. 
There were no significant differences in the comparison between HRV features among sleep stages 
for patients and for controls except for VLF power in patients and for SDNN, total power and 
LF/HF ratio in control subjects (see Tables S2 and S3). 
 
Correlation analysis  
Correlation analysis between clinical parameters (ESS, PSQI, disease duration) and sleep scoring 
parameters (TST, SE, SL, WASO%, N1%, N2%, N3%, REM%) showed a positive correlation 
between ESS scores and the percentage of N3 sleep stage, while a negative correlation emerged 
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 11 
between PSQI and the percentage of N2 sleep stage. No correlations were found between both ESS 
and PSQI and TST and SE. Moreover, a positive correlation was found between disease duration 
and the percentage of WASO as well as a negative correlation between disease duration and TST. 
A positive correlation was found between ALSFRS score and percentage of N2 sleep stage and a 
negative correlation between ALSFRS score and percentage of N3 sleep stage (Table 7). 
In ALS patients, correlation analysis between ALSFRS score and HRV features showed a positive 
correlation between ALSFRS score and VLF, by contrast, no correlations were observed between 
HRV parameters and disease duration. 
In ALS patients, no correlations were found between CAP parameters and clinical parameters 
(ALSFRS and disease duration) or HRV parameters. 
In control subjects, correlation analysis between CAP and HRV features showed a positive 
correlation trend, although not statistically significant, between some CAP features, such as A1% 
and A3% and A1/A3 ratio, and some HRV parameters, such as total power, VLF and LF both 
during light sleep (N1 and N2 sleep stages) and during the entire NREM sleep.  
 
Discussion 
Although motor dysfunction is predominant in ALS, involvement of other systems including ANS 
has been documented.
3–6,8–10
 Sleep is the ideal condition for studying the ANS, but only few 
overnight PSG studies have been carried out in patients affected by ALS
13,15
 none of which 
evaluating sleep microstructure. Moreover, to our knowledge, this is the first extensive evaluation 
of ANS during sleep, with regard to sleep stages (N1, N2, N3, and REM), nocturnal wakefulness 
and CAP parameters. 
The ALS patients of our study showed a marked disruption of sleep architecture, characterized by 
repetitive stage transitions (Fig. 1a), decreased SE and TST, reduced percentages of REM sleep, 
and increased amounts of WASO and stage N1. Enhancement of N1 led to an inversion of the 
N1/N3 ratio (p<0.0001), that is approximately four-fold higher compared to healthy controls, 
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 12 
indicating a predominance of light sleep in ALS patients, while deep sleep appeared statistically 
unaffected in percentage but highly fragmented and randomly distributed throughout the night. 
These results are in accordance with previous findings in ALS patients.
35,36
 Another interesting 
finding is the unusual distribution of the N3 sleep stage along the night, that in normal conditions 
N3 is predominant in the first part of the night, conversely, in these patients, it is spread throughout 
the sleep recording time, being almost totally missing in some cases (Fig 1a). The abnormal 
behavior of the homeostatic sleep process may be related to the increased amounts of wakefulness 
and stage shifts in the first part of the night and to the reduction of CAP A1 subtypes, conditions 
that hamper the build-up and consolidation of slow wave sleep in the first part of the night.
37
 
Accordingly, our preliminary results
38
 showed that patients affected by ALS with the most severe 
pathology had the most unstable sleep patterns, with % of high frequency band (HFC) < 4%, 
evaluated by means of cardio-pulmonary coupling (CPC),
39
 indicating a more arousable sleep. 
Impairment of sleep microstructure was another interesting finding in our ALS patients. Compared 
to healthy controls, ALS patients presented a significant reduction of CAP time and CAP rate and 
an inversion of A1/A3 ratio due to the reduced amounts of A1 subtypes and the increased amounts 
of A3 phases. The strong relationship between ANS activity and sleep microstructure,
40
 the 
“inverted” CAP-related A1/A3 ratio and the predominance of light sleep indicate a shift toward an 
increased sympathetic tone and a reduction of parasympathetic activity during sleep in ALS 
patients. In addition, a subclinical involvement of cardiac ANS, mostly of vagal nerve efferents, and 
was demonstrated by HRV assessment during both sleep (NREM and REM) and wakefulness. In 
fact, compared to healthy controls, ALS patients presented a reduction of HRV features, both in 
time and frequency domain, influenced by sympathetic and vagal systems. In particular, full-night 
analysis revealed a reduction of pNN20 (a feature dependent on vagal activity, correlated to the HF 
component)
28
, and of LF component (a feature that reflects baroreceptor, vagal and sympathetic 
influences)
41
, and of LF/HF ratio, which is considered a marker of the sympatho-vagal balance 
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 13 
(although this assumption is not totally accepted, mostly because LF power is not a pure index of 
the ANS drive)
41
.  
State-specific analysis showed that wakefulness, NREM light sleep and REM sleep were 
characterized by a reduction of several time- and frequency-domain features, with alteration of the 
LF/HF ratio during REM sleep, indicating a global impairment of cardiac ANS in patients affected 
by ALS. In deep sleep, only LF was significantly lower in ALS group, reflecting the reduced 
amounts of subtypes A1, which physiologically dominate the SWS. Interestingly, the total-power, 
that mirrors the global reactivity of the HR, was significantly lower in patients compared to controls 
during both wakefulness and sleep and during both light NREM sleep and REM sleep, indicating a 
reduction of the variability of HR. Accordingly, SDNN, pNN20 and HF power, which are 
influenced by vagal activity, were decreased in patients during wakefulness, light NREM sleep and 
REM sleep.  
Overall, these findings indicate that patients affected by ALS present a subclinical dysfunction of 
the cardiac autonomic function and a reduction of HRV likely due to vagal impairment, in 
accordance with previous reports on the involvement of parasympathetic system in ALS patients.
4,42
  
It is well known that decreased HRV is associated with increased risk in mortality for cardiac 
sudden arrest,
5,6
 and low HRV is a strong predictor of increased mortality for coronary events, 
which occurs more frequently at night.
5
 Therefore, impairment of ANS in ALS patients might 
represent a possible risk factor for sudden death during sleep. 
The negative correlation between severity of disease (ALSFRS score) and the power of VLF of the 
whole night, indicates that the worse the ALS severity the lower the VLF power. VLF power is 
strongly correlated with the time-measure SDNNI, but its uncertain underlying physiological 
mechanism seems to be generated by the cardiac intrinsic nervous system with a contribution from 
the parasympathetic nervous system and influences by the sympathetic nervous system. 
41
 This data 
is remarkable because VLF rhythms seem to be fundamental for health, and low VLF power has 
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 14 
been associated with all-cause mortality, including arrhythmic death. Basing on this result patients 
with the more severe ALS may have a higher risk of sudden death due to arrhythmias. I 
In our study no other correlations have been found between HRV features and disease severity and 
disease duration, indicating that impairment of cardiac autonomic control in ALS may start early 
and in all stages of the disease.  
The lack of correlation between curtailed PSG parameters, such as TST and SE, and daytime 
sleepiness (measured by ESS) and perceived quality of sleep (measured by PSQI) was another 
interesting finding. These results could be partially explained by the preservation of N3 percentages 
(similar to healthy controls) and by a cognitive impairment linked to the reduction of the A1 
components of CAP, which are involved in sleep-related memory processes.
43,44
 
In healthy controls, CAP and HRV features showed a positive correlation trend between A1%, 
A3% and A1/A3 ratio with total-power, VLF and LF. In contrast, no significant correlation between 
CAP metrics and HRV parameters was not found in ALS patients, suggesting a degeneration of the 
central neural network involved in the generation of CAP and in the control of the ANS, that seem 
to be functionally interconnected.
40
 In particular, the thalamo-cortical pathways, which modulate 
the transient EEG oscillations that characterize the phases A of CAP,
40
 are known to be linked to 
the limbic system and a large area extended from hypothalamus to medulla oblungata.
45
 
Involvement of hypothalamus in ALS has been documented by several studies showing 
hypothalamic TDP-43 inclusions or hypothalamus atrophy (also present in familial pre-
symptomatic gene carriers) and appears to be correlated to early onset and disease progression.
7
 
The impairment of vagal cardiac autonomic system, demonstrated by decreased HRV features, and 
the absence of correlation between HRV features and disease duration indicate that in our ALS 
patients the involvement of ANS is primitive, and not directly correlated with disease progression, 
although it may worsen with the latter stages of the disease, as shown by the correlation between 
ALSFRS and VLF power.  
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 15 
In conclusion, the disruption of interconnected networks due to a degenerative process conduct to 
an imbalance of the ANS which promotes a severe macro- and microstructural sleep fragmentation 
which in turn contributes, like a “vicious cycle”, to an increased instability of the autonomic 
balance (Fig 2). 
Our study confirms that ALS is likely a multisystem neurological syndrome since the early stages 
of the disease. Therefore, during the diagnostic process it is recommended to investigate, beside the 
motor system, also sleep, cognitive and autonomic functions. 
Taking into account the risk of sudden death during sleep due to decreased HRV, the relationships 
between disturbed sleep and cognitive deficits
43,46
 in neurodegenerative diseases, the well-known 
association between cognitive deficits and poor prognosis in ALS,
47
 and the impact of nocturnal 
hypoventilation in anticipating respiratory failure,
11
 it is recommended, during routine exams, to 
assess autonomic function and sleep, in order to early identify and adequately treat any 
comorbidity, aiming at improving the quality of life and possibly prolong life expectancy.  
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AHI: apnea-hypopnea index 
ALS: amyotrophic lateral sclerosis 
ALSFRS: amyotrophic lateral sclerosis functional rating scale 
ALSSS: amyotrophic lateral sclerosis severity scale 
ANS: autonomic nervous system 
A1: phase A1 of cyclic alternating pattern 
A2: phase A2 of cyclic alternating pattern 
A3: phase A3 of cyclic alternating pattern 
BQ: Berlin questionnaire 
BR: breathing rate 
CAP: cyclic alternating pattern 
ECG: electrocardiogram 
EEG: electroencephalogram 
EMG: electromyography 
ESS: Epworth sleepiness scale 
HF: high frequencies 
HR: heart rate 
HRV: heart rate variability 
IRLSRS: international restless legs syndrome severity rating scale  
LF: low frequencies 
NCAP: not CAP 
NN: intervals between normal R peaks of QRS 
NREM: not REM sleep 
N1: N1 phase of NREM sleep 
N2: N2 phase of NREM sleep 
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N3: N2 phase of NREM sleep 
NS: not statistically significant 
ODI<3%: oxygen desaturation index below 3% 
pNN20: proportion of interval differences of successive NN intervals greater than 20 ms  
pNN50: proportion of interval differences of successive NN intervals greater than 50 ms 
PSG: polysomnography 
PSQI: Pittsburgh sleep questionnaire index 
RBDSQ: REM behavior disorder screening questionnaire 
REM: rapid eye movement sleep stage 
RLSDI: restless legs syndrome diagnostic interview 
RMSSD: square root of the mean squared differences of successive NN intervals 
RR: interval between R peaks of QRS 
SDANN: standard deviation of the average NN interval 
SDNN: standard deviation of the NN intervals 
SE: sleep efficiency 
SL: sleep latency 
SpO2: peripheral saturation of O2 
TDP-43: Trans-Activator Regulatory DNA binding protein 43 kDa 
TL90: percentage of TST spent with SpO2 below 90% 
TST: total sleep time 
VLF: very low frequencies 
WASO: wakefulness after sleep onset 
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Tables legend 
 
Table 1 
Exclusion criteria for patients and control subjects 
 
Table 2 
Questionnaires and evaluation scales used for evaluating sleep and disability  
 
Table 3: demographic and clinical data of the 31 patients enrolled for CAP and HRV analysis.  
Legend: ALSFRS: Amyotrophic Lateral Sclerosis – Functional Rating Scale; ALSSS: Amyotrophic 
Lateral Sclerosis Severity Scale; ESS: Epworth Sleepiness Scale; PSQI: Pittsburgh Sleep 
Questionnaire Index; ns: not statistically significant 
For comparison of parameters obtained by sleep scoring between patients and controls Student’s t 
test was used. Differences were considered significant when p value were <0.05. 
 
Table 4: sleep scoring parameters in patients and controls.  
Legend: TST: Total Sleep Time; SL: Sleep latency; SE: sleep efficiency; WASO: wake after sleep 
onset. N1/N3: the ratio between the percentage of N1 and N3 sleep stages; AHI: apnea-hypopnea 
inex; ODI<3%: oxygen desaturazion below 3% index; mean SpO2: mean value of SpO2 recorded 
during the night; TL90%: percentage of time spent with SpO2 below 90%; 
a
significance based on 
Student’s t-test; bsignificance based on Mann-Whitney test; NS: not statistically significant. 
For comparison of parameters obtained by sleep scoring between patients and controls Student’s t 
test was used for data with Gaussian distribution, Mann-Withney test was used for data without 
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normal distribution. Gaussian distribution of data was evaluated by means of D’Agostino & 
Pearson Normality test. Differences were considered significant when p value were <0.05. 
 
Table 4-bis Heart rate and respiratory rate parameters in patients and scoring 
Legend: HR: heart rate; LS: light sleep; N1: the phase N1 of NREM sleep; N2: the phase N2 of 
NREM sleep; DS: deep sleep equivalent to the phase N3 of NREM sleep; BR: breathing rate; NS: 
not statistically significant. For comparison of parameters obtained by sleep scoring between 
patients and controls Student’s t test was used for data with Gaussian distribution. Gaussian 
distribution of data was evaluated by means of D’Agostino & Pearson Normality test. Differences 
were considered significant when p value were <0.05. 
 
Table 5: CAP (Cyclic Alternating Pattern) scoring parameters in patients and controls.  
Legend: A1/A3: the ratio between the percentage of A1 and A3 phases of CAP; 
a
: significance 
based on Student’s t-test; b: significance based on Mann-Whitney test; NS: not statistically 
significant. 
For comparison of parameters obtained by CAP scoring between patients and controls Student’s t 
test was used for data with Gaussian distribution, Mann-Withney test was used for data without 
normal distribution. Gaussian distribution of data was evaluated by means of D’Agostino & 
Pearson Normality test. Differences were considered significant when p value were <0.05. 
 
Table 6: p-values from the Kruskal-Wallis test between ALS and controls. The top part of the table 
reports values of the HRV features calculated for the whole night, while the bottom part reports 
values computed on 5-min epochs and then grouped by sleep state using median values. P values 
below 0.05 are highlighted in bold and represent significant differences. 
Legend: Time Domain Features: MeanNN: Mean of all the NN intervals; SDNN: standard 
deviation of the NN intervals over the entire recording; SDANN: standard deviation of the average 
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NN intervals calculated over 5 minutes; SDNN index: mean of the 5-minute standard deviations of 
NN intervals calculated over the entire recording; RMSSD: square root of the mean squared 
differences of successive NN intervals; pNN50: proportion of interval differences of successive NN 
intervals greater than 50 ms; pNN20: proportion of interval differences of successive NN intervals 
greater than 20 ms. Frequency Domain Features: Tot power:  the total spectral power of the HRV 
between 0 Hz and its Nyquist frequency; VLF: amplitude of the HRV power spectrum in the very 
low frequency (<0.04 Hz) range; LF: Amplitude of the HRV power spectrum in the low frequency 
(0.04-0.15 Hz) range; HF: Amplitude of the HRV power spectrum in the high frequency (0.15-0.4 
Hz) range; LF/HF: the ration between HF to LF. 
 
Table 7: Assessment of correlation between HRV features in time- and frequency- domain of 
whole night recording and ALSFRS score of patients affected by ALS. 
Legend: ALSFRS: Amyotrophic lateral sclerosis- functional rating scale; CI: confidence interval; 
NS: not statistically significant. 
Parameters obtained by sleep scoring (not shown I the table), CAP scoring (not shown in the table) 
and HRV analysis were correlated with each other (not shown in the table) and with clinical 
features, namely ALSFRS score, PSQI and ESS by calculating the Spearman correlation coefficient 
(Spearman’s r).  
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Figure Legend 
Figure 1 
Hypnogram (a) and graphic representation of Cyclic Alternating Pattern (b1, b2), and heart rate 
variability (c) of 1-night video-PSG of a patient affected by ALS.  
A1, A2, A3: phases A of CAP; B: phase B of CAP; NCAP: brain electrical EEG without CAP  
 
Figure 2  
Graphic representation of relationship between sleep, autonomic nervous system and cyclic 
alternating pattern. 
In subjects with ALS the degeneration process conducts to an imbalance of the ANS which move 
towards (causing) a severe macro and microstructure sleep fragmentation that in turn contribute, 
like a “vicious cycle”, to increase the sympathetic instability. 
 
 
Supplementary material 
Fig S1: Phases A of CAP 
Method S1: HRV assessment 
Table S1: Respiratory and movement data of PSG of patients and control subjects 
Table S2: Comparison between time- and frequency-domain features among the different sleep 
stages in patients 
Table S3: Comparison between time- and frequency-domain features among the different sleep 
stages in control subjects 
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Figure 1 
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Figure 2 
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Table 1 Exclusion criteria for patients and control subjects 
 
Exclusion criteria for patients 
 
Exclusion criteria for control subjects 
Age<18 years  
Pregnant female patients  
Patients who denied consent 
Comorbidities: cancer, alterations of heart 
rhythm, coronary artery disease, heart failure, 
diabetes  
Psychiatric disorders, kidney or liver disease, 
sleep disorders (Apnea-Hypopnea Index >15, 
Periodic Leg Movements Index> 15) Drugs and 
medicaments: cancer and cardioactive drugs 
(namely beta-blockers, beta-agonists, calcium 
channels blockers, antiarrhythmic drugs, 
antidepressants, antipsychotics, AchE inhibitors, 
alpha receptors agonists and antagonists).  
Patients under NIV (not invasive ventilation) 
Patients whose severe clinical conditions did not 
allow one night in the sleep lab  
 
Age<18 years 
Pregnant females 
Denied consent 
Comorbidities: any cardiac disorders, diabetes 
or diagnosed psychiatric disorders, kidney or 
liver disease, cancer, any sleep disorders  
No intake of medication affecting the ANS and 
all psychotropic drugs affecting EEG and CAP.   
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Table 2 Questionnaires and evaluation scales used for evaluating sleep and disability  
Questionnaire/scale Significance 
Epworth Sleepiness Scale – ESS 
A self-administered questionnaire that assesse 
diurnal sleep propensity 
Pittsburgh Sleep Questionnaire Index – 
PSQI 
A self-administered questionnaire that 
evaluates sleep habits of the previous month 
Berlin Questionnaire – BQ  
A screening test for OSAS (obstructive sleep 
apnea syndrome) 
Restless Legs Syndrome Diagnostic 
Interview – RLSDI 
A 4-questions interview required for 
diagnosing RLS 
Restless Legs Syndrome Severity Rating 
Scale – IRLSRS 
A 10-items interview for assessing the presence 
and the severity of the RLS 
REM behavior Disorder Screening 
Questionnaire – RBDSQ 
A self-administered questionnaire that 
evaluates the presence of RBD 
Revised ALS Functional Rating Scale – 
ALSFRS-revised 
A 12- or 13-items scale (depending on the 
presence of respiratory insufficiency) that 
evaluates the severity of the disability due to 
pregressive motor neurons degeneration ALS 
ALS Severity Scale – ALSSS 
A 4-items scale that evaluates the severity of 
the disability due to pregressive motor neurons 
degeneration ALS 
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Table 3 demographic and clinical data of the 31 patients enrolled for CAP and HRV analysis.  
 
 Patients (n=31) Controls (n=26)  
 mean  S.D. mean  S.D p value 
Age (years) 63.94  10.17 62,19  13.93 0.2740 (ns) 
ESS 5.39  3.45 5.04  2.25 0.6604 (ns) 
PSQI 8.90  4.44 8.46  2.30 0.6492 (ns) 
Age at disease onset (years) 60.74  10.93    
Disease duration (years) 3.26  4.78    
ALSFRS 32.38  8.86    
ALSSS 29.17  5.42    
 
Legend: ALSFRS: Amyotrophic Lateral Sclerosis – Functional Rating Scale; ALSSS: Amyotrophic 
Lateral Sclerosis Severity Scale; ESS: Epworth Sleepiness Scale; PSQI: Pittsburgh Sleep 
Questionnaire Index; ns: not statistically significant 
For comparison of parameters obtained by sleep scoring between patients and controls Student’s t 
test was used. Differences were considered significant when p value were <0.05. 
 
D
ow
nloaded from
 https://academ
ic.oup.com
/sleep/advance-article-abstract/doi/10.1093/sleep/zsz164/5532811 by U
niversità di C
agliari user on 19 July 2019
Ac
ce
pte
d M
an
us
cri
pt
 
 32 
Table 4 sleep scoring parameters in patients and controls.  
 
 Patients (n=31) Controls (n=26)  
 mean  S.D. mean  S.D. p value 
TST (min) 346.73  101.31 417.56  69.01 0.0025
a 
SL (min) 31.5  23.57 49.66  133.48 NS (0.1416)
b
 
SE (%) 68.27  16.81 84.77  13.83 <0.0001
b
 
WASO (% of SPT) 25.78  14.08 7.24  4.66 <0.0001
a
 
N1 (% of TST) 20.83  9.59 7.60  4.71 <0.0001
a
 
N2 (% of TST) 41.23  10.68 43.97  10.50 NS (0.6070)
a
 
N3 (% of TST) 22.38  11.22 26.22  8.64 NS (0.2326)
a
 
REM (% of TST) 15.55  8.09 21.49  5.88 0.0065
a
 
N1/N3 % 1.52  2.06 0.36  0.36 <0.0001
b
 
 
Legend: TST: Total Sleep Time; SL: Sleep latency; SE: sleep efficiency; WASO: wake after sleep 
onset. N1/N3: the ratio between the percentage of N1 and N3 sleep stages; AHI: apnea-hypopnea 
inex; ODI<3%: oxygen desaturazion below 3% index; mean SpO2: mean value of SpO2 recorded 
during the night; TL90%: percentage of time spent with SpO2 below 90%; 
a
significance based on 
Student’s t-test; bsignificance based on Mann-Whitney test; NS: not statistically significant. 
For comparison of parameters obtained by sleep scoring between patients and controls Student’s t 
test was used for data with Gaussian distribution, Mann-Withney test was used for data without 
normal distribution. Gaussian distribution of data was evaluated by means of D’Agostino & 
Pearson Normality test. Differences were considered significant when p value were <0.05. 
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Table 4-bis Heart rate and respiratory rate parameters in patients and scoring 
 
 
 Patients (n=31) Controls (n=26)  
 mean  S.D. mean  S.D. p value 
HR whole night 68.33  9.32 64.95  6.48 NS (0.1489) 
HR NREM 66,73  8.58 64.01  6.60 NS (0.2011) 
HR LS (N1+N2) 66.60  8.62 63.40  6.19 NS (0.1263) 
HR DS 67.37  8.52 65.53  7.85 NS (0.4157) 
HR REM 66.91  9.45 65.38  5.85 NS (0.4857) 
HR wake 74.07  8.40 71.27  7.60 NS (0.2044) 
BR whole night 20.76  3.81 16.93  2.28 <0.0001 
BR NREM 20.39  3.64 16.77  2.28 <0.0001 
BR LS (N1+N2) 20.55  3.80 16.76  2.24 <0.0001 
BR DS (N1+N2) 19.86  3.60 16.75  2.28 <0.001 
BR REM 21.26  4.75 17.18  3.13 <0.001 
BR wake 21.89  4.06 18,77  3.13 <0.01 
 
Legend: HR: heart rate; LS: light sleep; N1: the phase N1 of NREM sleep; N2: the phase N2 of 
NREM sleep; DS: deep sleep equivalent to the phase N3 of NREM sleep; BR: breathing rate; NS: 
not statistically significant. For comparison of parameters obtained by sleep scoring between 
patients and controls Student’s t test was used for data with Gaussian distribution. Gaussian 
distribution of data was evaluated by means of D’Agostino & Pearson Normality test. Differences 
were considered significant when p values were <0.05. 
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Table 5 CAP (Cyclic Alternating Pattern) scoring parameters in patients and controls.  
 
 Patients (n=31) Controls (n=23)  
 mean  S.D mean  S.D p value 
CAP time (min) 100.52  65.21 141.29  36.97 0.0096
a
 
CAP rate  32.07  18.02 43.10  10.23 0.011
a
 
A phases – total (n°) 206.58  145.33 291.26  79.67 0.0015
b
 
A1 % 28.78  16.51 51.59  13.65 <0.0001
b
 
A2 % 20.15  8.32 19.03  665 NS (0.5958)
a
 
A3 % 51.07  19.40 29.38  12.03 <0.0001
b
 
A1/A3 % 0.80  0.72 2.53  1.33 <0.0001
b
 
 
Legend: A1/A3: the ratio between the percentage of A1 and A3 phases of CAP; 
a
: significance 
based on Student’s t-test; b: significance based on Mann-Whitney test; NS: not statistically 
significant. 
For comparison of parameters obtained by CAP scoring between patients and controls Student’s t 
test was used for data with Gaussian distribution, Mann-Withney test was used for data without 
normal distribution. Gaussian distribution of data was evaluated by means of D’Agostino & 
Pearson Normality test. Differences were considered significant when p value were <0.05. 
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Table 6 p-values from the Kruskal-Wallis test between ALS and controls.  
The top part of the table reports values of the HRV features calculated for the whole night, while 
the bottom part reports values computed on 5-min epochs and then grouped by sleep state using 
median values. P values below 0.05 are highlighted in bold and represent significant differences. 
  
Whole night analysis 
 
 MeanNN SDNN SDANN SDNNi RMSSD pNN50 pNN20 TotPWR VLF LF HF LF/HF 
 0.178 0.184 0.461 0.068 0.236 0.173 0.027 0.194 0.073 0.049 0.665 0.010 
  
5 min epochs - median analysis (Sleep state analysis) 
 
 MeanNN SDNN SDANN SDNNi RMSSD pNN50 pNN20 TotPWR VLF LF HF LF/HF 
wake 0.276 0.002 0.074 0.001 0.034 0.039 0.012 0.002 0.004 0.001 0.011 0.120 
NREM 0.361 0.033 0.095 0.081 0.120 0.097 0.033 0.036 0.023 0.005 0.049 0.962 
LS 0.184 0.015 0.047 0.033 0.073 0.064 0.010 0.017 0.009 0.003 0.019 0.962 
DS 0.381 0.152 0.106 0.354 0.259 0.540 0.109 0.162 0.157 0.040 0.152 0.919 
REM 0.728 0.017 0.244 0.065 0.012 0.011 0.017 0.016 0.055 0.000 0.014 0.027 
 
 
Legend: Time Domain Features: MeanNN: Mean of all the NN intervals; SDNN: standard 
deviation of the NN intervals over the entire recording; SDANN: standard deviation of the average 
NN intervals calculated over 5 minutes; SDNNi: mean of the 5-minute standard deviations of NN 
intervals calculated over the entire recording; RMSSD: square root of the mean squared differences 
of successive NN intervals; pNN50: proportion of interval differences of successive NN intervals 
greater than 50 ms; pNN20: proportion of interval differences of successive NN intervals greater 
than 20 ms. Frequency Domain Features: Tot power:  the total spectral power of the HRV between 
0 Hz and its Nyquist frequency; VLF: amplitude of the HRV power spectrum in the very low 
frequency (<0.04 Hz) range; LF: Amplitude of the HRV power spectrum in the low frequency 
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(0.04-0.15 Hz) range; HF: Amplitude of the HRV power spectrum in the high frequency (0.15-0.4 
Hz) range; LF/HF: the ration between HF to LF. 
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Table 7 Assessment of correlation between HRV features in time- and frequency- domain of whole 
night recording and ALSFRS score of patients affected by ALS. 
 
Whole 
night 
ALSFRS 
vs 
meanNN 
ALSFRS 
vs 
SDNN 
ALSFRS 
vs  
SDANN 
ALSFRS 
vs 
SDNNi 
ALSFRS 
vs  
RMSSD 
ALSFRS 
vs 
pNN50 
ALSFRS 
vs 
pNN20 
ALSFRS 
vs  
totPower 
ALSFRS  
vs  
VLF 
ALSFRS  
vs  
LF 
ALSFRS  
vs  
HF 
ALSFRS 
vs  
LF/HF 
Spear
man r 
0.26 0.23 0.12 0.36 0.12 0.14 0.25 0.25 0.38 0.33 0.25 -0.03 
95% 
CI 
-0.12 to 
0.58 
-0.16 to 
0.56 
-0.27 to 
0.48 
-0.01 to 
0.66 
-0.27 to 
0.47 
-0.25 to 
0.49 
-0.14 to 
0.57 
-0.14 to 
0.57 
0.01 to 
0.66 
-0.05 to 
0.63 
-0.14 to 
0.57 
-0.40 to 
0.35 
P value 
(two-
tailed) 
NS (0.17) NS (0.22) NS (0.53) 
NS 
(0.052) 
NS (0.55) NS (0.48) NS (0.19) 
NS 
(0.195) 
0.0414 NS (0.08) NS (0.19) NS (0.86) 
 
Legend: ALSFRS: Amyotrophic lateral sclerosis- functional rating scale; CI: confidence interval; 
NS: not statistically significant. 
Parameters obtained by sleep scoring (not shown I the table), CAP scoring (not shown in the table) 
and HRV analysis were correlated with each other (not shown in the table) and with clinical 
features, namely ALSFRS score, PSQI and ESS by calculating the Spearman correlation coefficient 
(Spearman’s r).  
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